

Substituted Quinazolines and Analogs and the Use Thereof

Abstract

5 The invention relates to novel quinazolines and heterocycles which are
antagonists or positive modulators of AMPA receptors, and the use thereof for
treating, preventing or ameliorating neuronal loss associated with stroke,
global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as
treating or ameliorating neurodegenerative diseases including Alzheimer's
10 disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's
disease and Down's syndrome, treating, preventing or ameliorating the adverse
consequences of the overstimulation of the excitatory amino acids, treating,
preventing or ameliorating anxiety, psychosis, convulsions, chronic pain,
glaucoma, retinitis, urinary incontinence, muscular spasm and inducing
15 anesthesia, as well as for treating or ameliorating the adverse consequences of
excitatory amino acid deficiency such as schizophrenia, myoclonus,
Alzheimer's disease and malnutrition and neural maldevelopment, and as
cognition and learning enhancers.